Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 4 25 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus PROCALAMINE.
Head-to-head clinical analysis: CLINIMIX E 4 25 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus PROCALAMINE.
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs PROCALAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides a source of amino acids and dextrose for parenteral nutrition; amino acids support protein synthesis, dextrose provides calories. Electrolytes maintain fluid and electrolyte balance.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
Intravenous infusion. Dose is based on nutritional requirements and metabolic tolerance. Typical adult dose: 1-2 L per day (providing 4.25% amino acids and 10% dextrose) at a rate not exceeding 4 mg/kg/min of dextrose. Administer via central line or peripheral vein if osmolarity permits.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
None Documented
None Documented
Amino acids: 0.5-1 hour (rapid clearance from plasma). Dextrose: effectively infinite as continuous infusion maintains steady state. Electrolytes: dependent on renal function and tubular handling.
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Amino acids: primarily deaminated in liver, urea excreted renally. Dextrose: metabolized to CO2 and water, with excess excreted renally as glucose. Electrolytes: renal excretion. No significant biliary/fecal elimination for components.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution